-
Signature
-
By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker
-
Stock symbol
-
ROIV
-
Transactions as of
-
Oct 15, 2025
-
Transactions value $
-
-$973,082
-
Form type
-
4
-
Date filed
-
10/17/2025, 09:00 PM
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Venker Eric |
President & Immunovant CEO |
C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM |
By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker |
2025-10-17 |
0001801917 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
ROIV |
Common Shares |
Options Exercise |
$6.57M |
+415K |
+27.55% |
$15.85 |
1.92M |
Oct 15, 2025 |
Direct |
|
| transaction |
ROIV |
Common Shares |
Sale |
-$7.02M |
-415K |
-21.6% |
$16.93 |
1.5M |
Oct 15, 2025 |
Direct |
F1 |
| transaction |
ROIV |
Common Shares |
Options Exercise |
$5.04M |
+318K |
+21.15% |
$15.85 |
1.82M |
Oct 16, 2025 |
Direct |
|
| transaction |
ROIV |
Common Shares |
Sale |
-$5.43M |
-318K |
-17.46% |
$17.05 |
1.5M |
Oct 16, 2025 |
Direct |
F1 |
| transaction |
ROIV |
Common Shares |
Options Exercise |
$1.88M |
+118K |
+7.87% |
$15.85 |
1.62M |
Oct 17, 2025 |
Direct |
|
| transaction |
ROIV |
Common Shares |
Sale |
-$2.02M |
-118K |
-7.29% |
$17.06 |
1.5M |
Oct 17, 2025 |
Direct |
F1 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
ROIV |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-415K |
-48.71% |
$0.00 |
437K |
Oct 15, 2025 |
Common Stock |
415K |
$15.85 |
Direct |
F2 |
| transaction |
ROIV |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-318K |
-72.88% |
$0.00 |
118K |
Oct 16, 2025 |
Common Stock |
318K |
$15.85 |
Direct |
F2 |
| transaction |
ROIV |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-118K |
-100% |
$0.00 |
0 |
Oct 17, 2025 |
Common Stock |
118K |
$15.85 |
Direct |
F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: